Ibnsina Pharma (EGX:ISPH)
Egypt flag Egypt · Delayed Price · Currency is EGP
13.11
+0.04 (0.31%)
At close: Aug 25, 2026

Ibnsina Pharma Cash Flow Statement

Millions EGP. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
1,074951.98614.56213.66172.58314.73
Depreciation & Amortization
353.29319.77242.2184.22182.53175.34
Other Amortization
32.9328.9923.536.575.642.75
Loss (Gain) From Sale of Assets
-45.93-71.51-2.95-1.39-1.21-4.25
Loss (Gain) From Sale of Investments
-3.12-0.32----
Loss (Gain) on Equity Investments
---1.561.13--
Provision & Write-off of Bad Debts
-8.5316.81215.3783.8565.53-45.13
Other Operating Activities
203.97355.58407.75173.02-41.7588.58
Change in Accounts Receivable
-3,224-5,276-6,643-4,068-85.2-1,284
Change in Inventory
-3,066-1,644-3,578-671.73-400.14-194.15
Change in Accounts Payable
5,4205,5558,1514,386558.68697.3
Change in Other Net Operating Assets
-174.17-307.05-356.43-181.75-94.79-91.78
Operating Cash Flow
563.55-71.06-926.58125.81361.88-340.43
Operating Cash Flow Growth
----65.23%--

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-1,200-734.6-260.05-354.04-798.46-147.53
Sale of Property, Plant & Equipment
146.02179.223.482.4550.4516.01
Sale (Purchase) of Intangibles
-32.32-38.17-22.89-8.23-26.18-11.15
Investment in Securities
-54.68-54.68----
Other Investing Activities
-----601.86-
Investing Cash Flow
-1,141-648.26-259.54-279.82-1,376-142.67

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-790.331,214875.52721.63960.4
Long-Term Debt Issued
-636.45577.29362.57712.39-
Total Debt Issued
635.221,4271,7911,2381,434960.4
Long-Term Debt Repaid
--422.09-874.29-471.63-21.53-250.65
Total Debt Repaid
-151.62-422.09-874.29-471.63-21.53-250.65
Net Debt Issued (Repaid)
483.61,005916.87766.461,412709.75
Issuance of Common Stock
----0.49-
Repurchase of Common Stock
-----185.74-14.4
Common Dividends Paid
-343.06-201.04-25.62-22.94-140.4-14.59
Financing Cash Flow
140.53803.65891.25743.521,087680.77

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Cash Flow
-437.384.33-294.87589.5272.67197.66

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-636.85-805.66-1,187-228.23-436.58-487.96
Free Cash Flow Growth
------
Free Cash Flow Margin
-0.77%-1.05%-2.13%-0.67%-1.96%-2.25%
Free Cash Flow Per Share
-0.63-0.80-1.18-0.23-0.43-0.38
Levered Free Cash Flow
-3,742-6,381-7,044-2,724-1,495-617.13
Unlevered Free Cash Flow
-2,323-4,782-5,990-2,071-1,197-439.52

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
2,0662,2711,375929.98481.52281.54
Cash Income Tax Paid
135.2755.38---76.32
Change in Working Capital
-1,044-1,672-2,425-535.24-21.45-872.44